Targets › CA7
1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology.
Reversible hydration of carbon dioxide. (UniProt, P43166)
Open in Phaseline: the race on CA7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Colorado, Denver | Methazolamide Carbonic anhydrase VII inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor | CA7, CA1, CA2, CA4 | Phase 4 | Glaucoma, Open-Angle | – |
Glaucoma, Open-Angle (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.